STAT1

Overview

Signal Transducer and Activator of Transcription 1 (STAT1) is a multifunctional transcription factor and a central mediator of cytokine signaling, particularly downstream of type I and type II interferons (IFN-α/β and IFN-γ). Encoded by the STAT1 gene in humans, this protein belongs to the STAT family, which shares a conserved domain architecture comprising an N-terminal domain, a coiled-coil domain, a DNA-binding domain, an SH2 domain, and a C-terminal transactivation domain. Upon cytokine stimulation, STAT1 is phosphorylated at tyrosine 701 by Janus kinases (JAKs), enabling it to form homodimers (gamma-activated factor, GAF) or heterotrimers (ISGF3 complex with STAT2 and IRF9) that translocate to the nucleus and drive transcription of interferon-stimulated genes (ISGs). This mechanism positions STAT1 as a pivotal regulator of innate and adaptive immune responses, antiviral defense, and cellular stress resolution.

Beyond its canonical immune functions, STAT1 exerts context-dependent roles in cell proliferation, apoptosis, and tumor suppression. Its activity is tightly regulated through phosphorylation, dephosphorylation, and protein–protein interactions that can either amplify or attenuate downstream inflammatory cascades. Dysregulation of STAT1 signaling has been implicated in a broad spectrum of pathological states, including viral acute lung injury, cancer radioresistance, immune checkpoint biology, cardiac arrhythmia, and graft-versus-host disease (GVHD), making it an increasingly prominent target in translational medicine.

Focus of Latest Publications

Recent investigations have revealed STAT1 as a convergence node for multiple disease-relevant signaling axes, spanning infectious disease, oncology, cardiology, and transplant immunology.

Acute Lung Injury and Viral Infection A 2026 study published in the Journal of Ethnopharmacology examined the therapeutic potential of the phenolic fraction derived from Elsholtzia penduliflora W.W.Sm. in a model of influenza A virus (IAV)-induced acute lung injury. The research identified the IDO-1–mitochondria–STAT1 axis as a key pathological signaling cascade in this context. Indoleamine 2,3-dioxygenase 1 (IDO-1), a rate-limiting enzyme in tryptophan catabolism with well-established immunosuppressive and inflammatory roles, was found to engage STAT1 through mitochondrial intermediary signaling. The phenolic fraction of the plant extract was reported to ameliorate lung injury by inhibiting this axis, highlighting STAT1 as a druggable effector downstream of metabolic-immunological crosstalk and implicating the mitochondrion as a critical signaling intermediary.

Radioresistance in lung cancer Research published in Molecular Cancer Research (2026) uncovered a novel protein–protein interaction between C1QBP (complement component 1 Q subcomponent-binding protein) and STAT1 in the context of lung cancer radioresistance. The study demonstrated that C1QBP interacts directly with STAT1 and promotes activation of the c-MYC–CHK1/CHK2 signaling axis, thereby conferring radioresistance to tumour cells. This finding positions STAT1 not merely as a transcriptional effector of immune signaling, but as a scaffold protein that can bridge metabolic regulators (C1QBP, a mitochondria-associated protein) with DNA damage response kinases, with important implications for adaptive radiation therapy strategies in thoracic malignancies.

cancer immunotherapy and PD-L1 Regulation A study in Cancer Letters (2026) elucidated the mechanistic basis by which the solute carrier transporter SLC5A11 mediates metformin-induced suppression of PD-L1, a central target in anti-PD1 immunotherapy. The work identified that SLC5A11-dependent activation of AMPK (encoded by PRKAA1) results in downstream inhibition of the JAK2–STAT1–IRF1 signaling cascade, which in turn reduces PD-L1 expression on cancer cells and enhances anti-tumor immune responses. This places STAT1 within a metabolic–immune checkpoint regulatory circuit, where pharmacological intervention with agents such as a metformin can reshape the tumor immune microenvironment by modulating STAT1 activity. The interplay between JAK2/STAT3 signaling pathway components and STAT1 in this context underscores the complexity of cytokine-driven transcriptional control over PD-1/PD-L1 axis biology.

Hypertension-Induced Atrial Fibrillation In Life Sciences (2026), HSP90 (specifically HSP90AA1) was identified as a master regulator orchestrating both mitochondrial dysfunction and STAT1/CCL8-driven inflammation in hypertension-induced atrial fibrillation (AF). Using arterial hypertension as a pathological context, this study demonstrated that STAT1-dependent inflammatory signaling amplifies cardiac remodeling and arrhythmogenesis downstream of HSP90 activity. Inhibiting HSP90 was found to suppress STAT1/CCL8-mediated inflammation while simultaneously mitigating mitochondrial dysfunction, positioning STAT1 as an effector linking heat shock chaperone biology to cardiac electrophysiological pathology.

Steroid-Refractory Graft-Versus-Host Disease A study published in Blood (2026) identified a STAT1–glucocorticoid receptor (GR) regulatory axis as a mechanistic driver of steroid-refractory acute GVHD. Using single-cell RNA sequencing and functional assays, the authors demonstrated that inflammatory cytokine signals induce STAT1 phosphorylation in CD28⁺ CD8⁺ effector memory T (Tem) cells, which in turn suppresses GR expression, leading to intrinsic glucocorticoid resistance. This finding provides a molecular explanation for clinical steroid refractoriness in GVHD and implicates JAK–STAT inhibition (e.g., with ruxolitinib) as a rational therapeutic strategy to restore glucocorticoid sensitivity by reducing STAT1 phosphorylation in disease-driving T cell subsets.

Key Publications

May C1QBP-STAT1 Interaction Promotes Activation of the c-Myc-CHK1/CHK2 Signaling Axis and Radioresistance in Lung Cancer. (Molecular cancer research : MCR, 2026, PMID 41642096): "we observed that C1QBP interacts with STAT1 and promotes c-Myc-CHK1/CHK2 signaling axis activation."
Apr SLC5A11 mediates metformin-induced PD-L1 suppression to enhance cancer immunotherapy through AMPK-IRF1 signaling. (Cancer letters, 2026, PMID 41690450): "SLC5A11-dependent activation of AMPK and subsequent JAK2-STAT1-IRF1 downregulation."
Apr CD28⁺ CD8⁺ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD. (Blood, 2026, PMID 41980031): "Single-cell RNA sequencing and functional assays implicated a STAT1-glucocorticoid receptor (GR) regulatory axis in which inflammatory cytokines induce STAT1 phosphorylation and suppress GR expression, consistent with intrinsic glucocorticoid resistance."
Apr Targeting HSP90 suppresses STAT1/CCL8-driven inflammation and mitigates mitochondrial dysfunction to attenuate hypertension-induced atrial fibrillation. (Life sciences, 2026, PMID 41720180): "This study sought to determine whether HSP90 acts as a master regulator that directly orchestrates mitochondrial dysfunction and inflammation to facilitate AF progression."
Apr Phenolic fraction of Elsholtzia penduliflora W.W.Sm. ameliorates influenza A virus-induced acute lung injury by inhibiting the IDO-1-mitochondria-STAT1 signaling axis. (Journal of ethnopharmacology, 2026, PMID 41794257): "Phenolic fraction of Elsholtzia penduliflora W.W.Sm. ameliorates influenza A virus-induced acute lung injury by inhibiting the IDO-1-mitochondria-STAT1 signaling axis."